Phase 1 Study of ADX-626 in Healthy Participants
ConditionHealthy Adult Participants
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-45
SponsorADARx Pharmaceuticals, Inc.
About this trial
This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).
Eligibility criteria
Qualifiers
Age 18 to 45 years at the time of informed consent
Males or women of non-childbearing potential (WONCBP)
Willing to comply with all study requirements while participating
Suitable venous access for blood sampling.
Disqualifiers
Significant medical condition such as hypertension, diabetes, cardiovascular disease, or cancer
History of bleeding or coagulation disorders, prior instances of major bleeding, or a family history of bleeding disorders.
Current infection
Participation in an interventional drug study within the last 90 days
Trial design
Treatments tested in this trial
- ADX-626
- Placebo
Treatment groups
44 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov